Abstract:Background: Bispecific T-cell engager (BiTE) is a targeted cancer immunotherapy which bridges T-cells to cancer cells, leading to activation of T-cells and killing cancer cells. While BiTEs have shown promising therapeutic efficacy in the treatment of hematological malignancies, therapeutic benefit of T-cell engagers are still in exploration for the treatment of solid tumors. Upregulation of immune checkpoints presents one of the major resistant mechanisms of the BiTE therapy. Here, we report a Trispecific Immune Check-point T-Cell Engager (TICTE) platform that targets both CD3 and PD-L1 simultaneously, which activates the T-cells as well as modulates the immune checkpoint blockade through the PD/PD-L1 axis, respectively. Our in vitro and in vivo studies demonstrate that the TICTEs induce dramatic and superior antitumor activity compared to its counterpart BiTE alone and the BiTE with anti-PD-L1 combination. These studies suggest that the TICTE (CD3xTAAxPD-L1), a single-agent with dual function of T-cell activation and immune checkpoint modulation, may provide an efficacious therapy to patients with solid tumors. Methods: Various TICTEs and BiTEs formats using the human IgG like architecture in three different TAA examples were generated. Their biophysical and biological activities were characterized. The cell binding activity and antigen density of cell lines were determined using flow cytometry. TDCC activity was measured using xCELLigence RTCA eSight system. In vitro efficacy was evaluated with multiple cancer cell lines and toxicity was evaluated with normal cell lines. The humanized xenograft models were utilized to investigate the TICTEs efficacy in vivo. Results: All TICTEs adopted their intended forms and showed robust biophysical properties. The TICTEs demonstrated the blockade activity of PD1/PD-L1 axis, as well preferentially targeted tumor cells expressed both TAAs and PD-L1. Large therapeutic windows were observed in three TAA (cMET, Her2 and Trop2) TICTEs. TICTEs showed a superior efficacy compared to counterpart BiTEs and combination of BiTE with a PD-L1 inhibitor in vitro and in vivo. Low cytokine release was observed compared to combination of BiTEs with a PD-L1 inhibitor, signifying the reduced risk of cytokine release syndrome (CRS) often associated with BiTE therapy. Conclusion: A single agent of the TICTE platform with unique biological property, superior efficacy and low cytokine release could represent an alternative combination immunotherapy for solid tumors. Citation Format: Xiufeng Wu, Xiaoshan Min, Yinan Wu, Lin Liu, Jing Zhou, Silvia Hudson, Shih-ping Chen, Jennifer Li, Will Draper, Subhadra Dash, Shidong Ma, Hang Chen, Zhulun Wang. TICTE, A trispecific T-cell engager with immune checkpoint modulation for solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6713.

Immunological Synapse Dynamics Induced by Bispecific T-cell Engagers Predict Clinical Pharmacodynamics and Tumor Evolution Across Anatomical Sites

Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance

A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor.

The landscape of bispecific T cell engager in cancer treatment

Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager Efficacy

Development of a Target Cell-Biologics-effector Cell (TBE) Complex-Based Cell Killing Model to Characterize Target Cell Depletion by T Cell Redirecting Bispecific Agents

Bispecific T‐cell engagers for cancer immunotherapy

Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions

Optimizing Clinical Translation of Bispecific T-cell Engagers Through Context Unification with a Quantitative Systems Pharmacology Model

Abstract 6713: TICTE, A trispecific T-cell engager with immune checkpoint modulation for solid tumors

Bionic Immunoactivator Copresenting Autophagy Promoting and Costimulatory Molecules for Synergistic Cancer Immunotherapy

T cell-engaging therapies - BiTEs and beyond

T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

Simultaneous evaluation of treatment efficacy and toxicity for bispecific T-cell engager therapeutics in a humanized mouse model

A Bi-Specific T Cell-Engaging Antibody Shows Potent Activity, Specificity, and Tumor Microenvironment Remodeling in Experimental Syngeneic and Genetically Engineered Models of GBM

Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency

Tuning the potency and selectivity of ImmTAC molecules by affinity modulation

Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110

Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?